Old Web
English
Sign In
Acemap
>
authorDetail
>
Tania J. Curcio
Tania J. Curcio
NewYork–Presbyterian Hospital
Minimal residual disease
Leukemia
Bone marrow
Interleukin-3 receptor
Immunology
2
Papers
51
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)
2015
Blood
B. Douglas Smith
Andrew W. Roberts
Gail J. Roboz
Mark DeWitte
Anna Ferguson
Linda Garrett
Tania J. Curcio
Kaysey F. Orlowski
Sue Dasen
Debra M. Bensen-Kennedy
Roland B. Walter
Show All
Source
Cite
Save
Citations (8)
First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse
2014
Blood
B. Douglas Smith
Gail J. Roboz
Roland B. Walter
Jessica K. Altman
Anna Ferguson
Tania J. Curcio
Kaysey F. Orlowski
Linda Garrett
Samantha Busfield
Megan Barnden
Brad Sedgmen
Souravi Ghosh
Sarah Hosback
Roslyn Davis
Allison Dyson
Sue Dasen
Mark DeWitte
Debra M. Bensen-Kennedy
Andrew W. Roberts
Show All
Source
Cite
Save
Citations (43)
1